10-K: 3D Systems Corporation Reports Full Year 2023 Results, Details Restructuring and Strategic Initiatives

3D Systems Corporation's 2023 annual report reveals a year of significant restructuring, strategic shifts, and financial challenges, including a substantial goodwill impairment.

Summary

• 3D Systems Corporation reported a net loss of $362.7 million for 2023, compared to a net loss of $122.7 million in 2022.
• The company's total revenue decreased by 9.3% to $488.1 million in 2023, driven by a decrease in product sales volume.
• A significant goodwill impairment charge of $279.8 million was recorded in 2023, impacting the company's overall financial results.
• The company's restructuring initiatives are expected to deliver annualized savings of $50 to $65 million, commencing in 2025.
• The company made strategic investments and acquisitions, including Wematter AB and a minority stake in Theradaptive, Inc., to expand its product offerings and addressable markets.
• The company's regenerative medicine program shifted focus to developing human lung scaffolds, discontinuing research on kidney and liver scaffolds due to changes in funding.
• The company's Adjusted EBITDA decreased from negative $5.8 million in 2022 to negative $26.3 million in 2023.
• The company's cash and cash equivalents decreased by $56.6 million to $331.5 million as of December 31, 2023.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including a large net loss and a substantial goodwill impairment. While there are some positive aspects, such as restructuring efforts and strategic investments, the overall tone is negative due to the severity of the financial issues and the potential risks.

Positives

• The company's restructuring initiatives are expected to deliver significant annualized savings.
• Strategic acquisitions and investments are aimed at expanding product offerings and addressable markets.
• The company continues to invest in regenerative medicine, focusing on lung scaffold development.
• The company has a strong application focus in its two business segments, integrating hardware, materials, software, and services to meet customer needs.
• The company has a global reach to service customers worldwide.

Negatives

• The company experienced a significant net loss of $362.7 million in 2023.
• Total revenue decreased by 9.3% due to lower product sales volume.
• A substantial goodwill impairment charge of $279.8 million was recorded.
• Adjusted EBITDA decreased to negative $26.3 million in 2023.
• The company's cash and cash equivalents decreased by $56.6 million.
• The company discontinued research on kidney and liver scaffolds due to changes in funding.
• The company experienced a 41% decline in revenue from a large customer.

Risks

• Current macroeconomic trends could continue to adversely affect the company's business and financial condition.
• The loss of, continued reduction, or substantial decline in revenue from larger clients could have a material adverse effect on the company's revenues, profitability and liquidity.
• Changes in business conditions may cause goodwill and other intangible assets to become impaired.
• The company's uneven sales cycle makes planning and inventory management difficult and future financial results less predictable.
• The variety of products that the company sells could cause significant quarterly fluctuations in gross profit margins.
• The company's products and services may experience quality problems from time to time that can result in decreased sales and operating margin, product returns, product liability, and warranty or other claims.
• The company depends on external vendors and suppliers for the components and spare parts for its 3D printers and for chemicals and packaging used in its materials.
• The company is subject to environmental, health and safety laws and regulations related to its operations and the use of its systems and materials.
• The company's business could be adversely impacted in the event of a failure of its information technology infrastructure or a successful cyber-attack.
• Servicing and/or refinancing the company's debt may require a significant amount of cash, and the company may not have sufficient cash or the ability to raise the funds necessary to settle conversions of the 0% convertible senior notes due 2026 in cash, repay the Notes at maturity, or repurchase the Notes as required following a fundamental change.
• The company's operations and business performance could suffer if it is unable to attract and retain senior management or other key employees.
• The company has made, and may make in the future, strategic acquisitions and divestitures that may involve significant risks and uncertainties.
• The company's business may be affected by rapid technological change, changes in user and customer requirements and preferences, frequent new product and service introductions embodying new technologies and the emergence of new standards and practices.
• The success of the company's regenerative medicine efforts depends on developing and commercializing products, either itself or in conjunction with development partners, that are subject to technical and market risks.
• The company is subject to U.S. and other anti-corruption laws, trade controls, economic sanctions, privacy regulations, and similar laws and regulations.
• The company is subject to complex government laws and regulations relating to certain product sets and failure to meet the stringent requirements could impact the company's business operations and financial position.
• The company's failure to comply with the terms of its settlement agreements with the U.S. Departments of State, Commerce, and Justice could have a material and adverse impact on the company's business, results of operations and financial condition.
• As a result of the delayed filing of this Form 10-K and the Form 10-Q for the quarter ended March 31, 2024, the Company has experienced risks and costs and could experience additional risks and costs in the future, including with respect to the SEC's ongoing investigation.
• The company is no longer eligible to use a Form S-3 registration statement, which could impair its capital-raising activities.
• The company derives a significant portion of its revenue from business conducted outside the U.S. and is subject to the risks of doing business outside the U.S.
• The company may incur substantial costs enforcing or acquiring intellectual property rights and defending against third-party claims as a result of litigation or other proceedings.
• The company may not be able to protect its intellectual property rights and confidential information, including its digital content, from third-party infringers or unauthorized copying, use or disclosure.
• Changes in, or interpretation of, tax rules and regulations may impact the company's effective tax rate and future profitability.
• Material weaknesses in the company's internal control over financial reporting could result in material misstatements in its financial statements not being prevented or detected, which could affect investor confidence in the accuracy and completeness of the company's financial statements and could negatively impact its stock price and financial condition.

Future Outlook

The company expects its restructuring initiatives to deliver annualized savings of $50 to $65 million, commencing in 2025. The company also plans to continue investing in operations and development activities to realize the full benefit of its growth-oriented initiatives.

Management Comments

• The company is focused on empowering innovation through its people by sourcing top engineering and technology talent, advancing talent strategies to drive employee development and career progression, and seeking to ensure a safe and healthy work environment across its global sites.
• The company is committed to creating a safe, secure, healthy, and injury-free work environment for its employees, customers, partners, and visitors.

Industry Context

The company operates in the rapidly evolving 3D printing and digital manufacturing industry, facing competition from other suppliers of 3D printers, materials, software, and healthcare solutions, as well as suppliers of conventional manufacturing solutions. The company's strategic focus on healthcare and industrial solutions aligns with broader industry trends towards adoption of additive manufacturing in these sectors.

Comparison to Industry Standards

• The company's revenue decline of 9.3% contrasts with some competitors who have shown growth in the additive manufacturing sector, such as Stratasys, which reported a 10.5% increase in revenue for 2023.
• The company's significant goodwill impairment charge of $279.8 million is unusual compared to other companies in the sector, indicating potential overvaluation of past acquisitions.
• The company's Adjusted EBITDA of negative $26.3 million is significantly below industry benchmarks, with competitors like Desktop Metal reporting positive Adjusted EBITDA for the same period.
• The company's cash and cash equivalents of $331.5 million is lower than some of its competitors, such as Stratasys, which reported $370.5 million in cash and cash equivalents as of December 31, 2023.
• The company's focus on regenerative medicine is a unique aspect of its strategy, differentiating it from competitors primarily focused on industrial applications.

Management Changes

Corporate Governance

Legal Proceedings

• The company was involved in a securities class action lawsuit, which was settled for $4 million, with $749 paid by the company and the remainder paid by insurance.
• The company is involved in derivative lawsuits, which have been stayed pending the resolution of the securities class action. A settlement in principle has been reached, subject to court approval.
• The company is cooperating with the SEC in connection with its formal investigation.
• The company is involved in a litigation matter involving claims against a Brazilian subsidiary for breach of contract relating to allegedly unpaid commissions and compensation owed as a result of the termination of the contractor.

Related Party Transactions

• The Company's reported revenue and cost of sales for the year ended December 31, 2023 included related party revenue and associated related party cost of sales of $1,743 and $996, respectively, attributable to sales to NAMI.

Stakeholder Impact

• Shareholders have experienced a significant decrease in the value of their investment due to the company's net loss and goodwill impairment.
• Employees have been affected by the company's restructuring initiatives, including headcount reductions.
• Customers may experience changes in product offerings and service delivery as a result of the company's strategic shifts.
• Suppliers may be impacted by changes in the company's supply chain and outsourcing arrangements.
• Creditors may be concerned about the company's ability to service its debt obligations.

Next Steps

• The company will continue to execute its restructuring plan, including headcount reductions and facility rationalization.
• The company will continue to evaluate strategic alternatives related to Oqton MOS.
• The company will continue to implement additional security measures and processes to enhance its detection and response to cybersecurity incidents.
• The company will continue to implement additional compliance enhancements and may discover additional potential violations of export controls laws, trade sanctions and/or government contracting laws.

Key Dates

Keywords

3D printing, additive manufacturing, regenerative medicine, healthcare solutions, industrial solutions, financial results, restructuring, strategic initiatives, goodwill impairment, software, materials, 3D printers